p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population

Urol Int. 2010;85(4):401-5. doi: 10.1159/000315991. Epub 2010 Jul 20.

Abstract

Introduction: Alterations in P53 and murine double minute 2 (MDM2) genes appear to be important in the development of many human tumors. We investigated the potential prognostic roles of p53 codon 72 and MDM2 309 and 1797 polymorphisms in prostate cancer after radical prostatectomy.

Patients and methods: Fifty southern Chinese with prostate cancer undergoing radical prostatectomy were included in this study. All polymorphisms were detected by PCR-RFLP. Their prognosis on biochemical recurrence was assessed using Kaplan-Meier analysis and Cox regression model.

Results: p53 codon 72 GG genotype was associated with increased biochemical recurrence compared with CG+CC genotypes and poorer PSA-free survival. It was also noted that GG genotype was an independent risk factor for biochemical recurrence after radical prostatectomy on multivariate analysis. No statistical difference was observed in MDM2 polymorphisms and prostate cancer prognosis.

Conclusion: Our data revealed that p53 codon 72 GG genotype carriers more frequently show biochemical recurrence than CG+CC genotypes carriers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Asian People / genetics*
  • Chi-Square Distribution
  • China
  • Codon
  • Disease-Free Survival
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Neoplasm Recurrence, Local / ethnology
  • Neoplasm Recurrence, Local / genetics*
  • Neoplasm Staging
  • Phenotype
  • Pilot Projects
  • Polymorphism, Single Nucleotide*
  • Proportional Hazards Models
  • Prostate-Specific Antigen / blood
  • Prostatectomy*
  • Prostatic Neoplasms / ethnology
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / surgery*
  • Proto-Oncogene Proteins c-mdm2 / genetics
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Codon
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2
  • Prostate-Specific Antigen